TCIM
GHDX

TIAA CREF Investment Management’s Genomic Health, Inc. GHDX Stock Holding History

TIAA CREF Investment Management’s Portfolio GHDX Stock Details GHDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$12.8M Sell
182,273
-30,726
-14% -$2.28M 0.01% 917
2018
Q4 		$13.7M Sell
212,999
-29,840
-12% -$2.09M 0.01% 807
2018
Q3 		$17.1M Buy
242,839
+66,873
+38% +$3.91M 0.01% 801
2018
Q2 		$8.87M Buy
175,966
+83,802
+91% +$3.33M 0.01% 1222
2018
Q1 		$2.88M Buy
92,164
+42,836
+87% +$1.42M ﹤0.01% 1899
2017
Q4 		$1.69M Sell
49,328
-1,718
-3% -$54.8K ﹤0.01% 2224
2017
Q3 		$1.64M Sell
51,046
-1,638
-3% -$51.7K ﹤0.01% 2278
2017
Q2 		$1.72M Sell
52,684
-18,549
-26% -$588K ﹤0.01% 2272
2017
Q1 		$2.24M Buy
71,233
+3,808
+6% +$113K ﹤0.01% 2073
2016
Q4 		$1.98M Sell
67,425
-1,971
-3% -$60.1K ﹤0.01% 2199
2016
Q3 		$2.01K Sell
69,396
-210
-0.3% -$5.85K ﹤0.01% 2169
2016
Q2 		$1.8M Buy
69,606
+1,590
+2% +$42.2K ﹤0.01% 2184
2016
Q1 		$1.69M Hold
68,016
– – ﹤0.01% 2179
2015
Q4 		$2.39M Buy
68,016
+9,156
+16% +$245K ﹤0.01% 2036
2015
Q3 		$1.25M Sell
58,860
-1,736
-3% -$44.7K ﹤0.01% 2430
2015
Q2 		$1.68M Buy
60,596
+3,763
+7% +$106K ﹤0.01% 2405
2015
Q1 		$1.74M Sell
56,833
-1,408
-2% -$44.8K ﹤0.01% 2309
2014
Q4 		$1.86M Sell
58,241
-4,038
-6% -$131K ﹤0.01% 2298
2014
Q3 		$1.76M Sell
62,279
-4,563
-7% -$127K ﹤0.01% 2304
2014
Q2 		$1.83M Sell
66,842
-41,359
-38% -$1.1M ﹤0.01% 2350
2014
Q1 		$2.85M Sell
108,201
-15,159
-12% -$435K ﹤0.01% 2020
2013
Q4 		$3.61M Buy
123,360
+3,404
+3% +$108K ﹤0.01% 1868
2013
Q3 		$3.67M Buy
119,956
+1,598
+1% +$53.4K ﹤0.01% 1811
2013
Q2 		$3.75M Buy
+118,358
New +$3.89M ﹤0.01% 1738

Other funds holding GHDX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TIAA CREF Investment Management's GHDX Position: Q1 2019 in Review

TIAA CREF Investment Management reduced its Genomic Health, Inc. (GHDX) stake by 14% in Q1 2019, selling an estimated $2.28M and leaving 182,273 shares worth $12.8M. The position accounts for 0.01% of the portfolio, ranked #917.

TIAA CREF Investment Management first reported a position in GHDX in Q2 2013 and has held it in 24 quarters since. The position peaked at $17.1M in Q3 2018. 267 funds tracked by Wall St. Rank hold GHDX as of Q1 2019.

  • TIAA CREF Investment Management held 182,273 shares of Genomic Health, Inc. worth $12.8M as of Q1 2019.
  • TIAA CREF Investment Management sold 30,726 Genomic Health, Inc. shares in Q1 2019, an estimated $2.28M.
  • Genomic Health, Inc. made up 0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #917 holding.
  • TIAA CREF Investment Management first reported a position in Genomic Health, Inc. in Q2 2013 and has held it in 24 quarters since.
  • TIAA CREF Investment Management's Genomic Health, Inc. position peaked at $17.1M in Q3 2018.
  • 267 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.